Bayer AG Stock Rises as New Drugs Propel Revenue Increases

Published: Jul 31, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer AG (BAYN) stock rose to a record as stronger-than-predicted demand for new drugs outweighed a drop at plastics revenue that the German manufacturer said makes its full-year sales forecast “ambitious.” Revenue from products including the Xarelto blood thinner and Eylea eye medicine “are progressing considerably better than expected,” Leverkusen-based Bayer said in a statement today. The company raised its forecast for sales from new drugs to 1.4 billion euros ($1.9 billion euros) from a previous estimate of 1 billion euros.

Help employers find you! Check out all the jobs and post your resume.

Back to news